NICE guidance may hinge on Erbitux access scheme
This article was originally published in Scrip
The UK's National Institute for health and Clinical Excellence(NICE) says it is not minded to recommendMerck Serono's Erbitux (cetuximab) for the first-line treatment of metastatic colorectal cancer patients in England and Wales. But the institute wants the manufacturer to clarify its economic analysis before a fourth appraisal committee meeting on April 1st.
You may also be interested in...
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.